EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Insulin Secretion Capacity as a Crucial Feature to Distinguish Type 1 From Type 2 Diabetes and to Indicate the Need for Insulin Therapy – A Critical Discussion of the ADA/EASD Consensus Statement on the Management of Type 1 Diabetes in Adults

Andreas Fritsche

Experimental and Clinical Endocrinology & Diabetes · 01.09.2023 · 131 (09) · 500-503

DOI: 10.1055/a-2016-8392 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 01.09.2023. Verfasst von Andreas Fritsche. Beteiligte Einrichtung: Department of Internal Medicine IV, Division of Diabetology, Endocrinology and Nephrology, Eberhard-Karls University Tübingen, Tübingen. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the recently published consensus statement on the treatment and management of type 1 diabetes issued by experts from the American (ADA) and European (EASD) diabetes societies, measurement of endogenous insulin secretion using fasting C-peptide is recommended as a diagnostic criterion. In contrast, our group recently suggested fasting C-peptide/glucose ratio (CGR) for the determination of endogenous insulin secretion. In addition, this ratio may turn out as a potential decision aid for pathophysiologically based differential therapy of diabetes. In this comment, the following points will be discussed: i) CGR as the basis of differential diagnosis of type 1 diabetes, ii) CGR as the basis of treatment decisions for or against insulin in diabetes, and iii) the ease of application of CGR in clinical practice. The use of CGR may complement the ADA/EASD recommendations and should provide a practical application in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1AdultHumansUnited StatesInsulinInsulin SecretionC-PeptideHypoglycemic Agents

Substanzen

InsulinC-PeptideHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Internal Medicine IV, Division of Diabetology, Endocrinology and Nephrology, Eberhard-Karls University Tübingen, Tübingen.
  • Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen.
  • German Center for Diabetes Research (DZD), Neuherberg.

Zitieren

APA

Fritsche, A. (2023). Insulin Secretion Capacity as a Crucial Feature to Distinguish Type 1 From Type 2 Diabetes and to Indicate the Need for Insulin Therapy – A Critical Discussion of the ADA/EASD Consensus Statement on the Management of Type 1 Diabetes in Adults. Experimental and Clinical Endocrinology & Diabetes, 131(09), 500-503. https://doi.org/10.1055/a-2016-8392

Vancouver

Fritsche A. Insulin Secretion Capacity as a Crucial Feature to Distinguish Type 1 From Type 2 Diabetes and to Indicate the Need for Insulin Therapy – A Critical Discussion of the ADA/EASD Consensus Statement on the Management of Type 1 Diabetes in Adults. Experimental and Clinical Endocrinology & Diabetes. 2023;131(09):500-503. doi:10.1055/a-2016-8392

BibTeX
@article{Fritsche2023,
  author = {Fritsche, Andreas},
  title = {Insulin Secretion Capacity as a Crucial Feature to Distinguish Type 1 From Type 2 Diabetes and to Indicate the Need for Insulin Therapy – A Critical Discussion of the ADA/EASD Consensus Statement on the Management of Type 1 Diabetes in Adults},
  journal = {Experimental and Clinical Endocrinology & Diabetes},
  year = {2023},
  volume = {131},
  number = {09},
  pages = {500--503},
  doi = {10.1055/a-2016-8392}
}
Kostenlos starten →